AR130077A1 - Substratos escindibles por proteasas, y métodos de uso de los mismos - Google Patents
Substratos escindibles por proteasas, y métodos de uso de los mismosInfo
- Publication number
- AR130077A1 AR130077A1 ARP230102011A ARP230102011A AR130077A1 AR 130077 A1 AR130077 A1 AR 130077A1 AR P230102011 A ARP230102011 A AR P230102011A AR P230102011 A ARP230102011 A AR P230102011A AR 130077 A1 AR130077 A1 AR 130077A1
- Authority
- AR
- Argentina
- Prior art keywords
- cleavable
- protease
- seq
- substrate
- acid sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/2408—Membrane-type matrix metalloproteinase-1 (3.4.24.80)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se divulgan polipéptidos aislados que incluyen un resto escindible que es substrato para al menos una proteasa (por ej., MT-SP1 y/o una MMP) y polipéptidos aislados que incluyen un substrato que tiene un primer resto escindible que es escindible por una primera proteasa y un segundo resto escindible que es escindible por una segunda proteasa. Se divulgan moléculas activables que incluyen los polipéptidos aislados. Se divulgan métodos para preparar y usar los polipéptidos aislados y las moléculas activables que incluyen los polipéptidos aislados en una variedad de aplicaciones terapéuticas, de diagnóstico y profilácticas. Reivindicación 1: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende un primer resto escindible (CM1) que es escindible por al menos una primera proteasa, y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el CM1 comprende la secuencia de aminoácidos de PXGL, en donde X es W, Y, F, R, K, Q, A, o M, opcionalmente en donde el CM1 comprende la secuencia de aminoácidos de PXGL, en donde X es W, Y, F, R, K, Q, o M. Reivindicación 57: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende: APRG (SEQ ID Nº 382), o un primer resto escindible (CM1) que escindible por una primera proteasa y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el substrato comprende un núcleo APR y el substrato comprende la secuencia de aminoácidos de APRSL (SEQ ID Nº 669), APRSY (SEQ ID Nº 39), APRSM (SEQ ID Nº 383), APRGL (SEQ ID Nº 672), APRGY (SEQ ID Nº 384), o APRGM (SEQ ID Nº 385). Reivindicación 89: Un polipéptido aislado que comprende un substrato escindible por una MMP y una serina proteasa, caracterizado porque el substrato comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 695, opcionalmente en donde el substrato comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 683. Reivindicación 90: Un polipéptido aislado que comprende un substrato, caracterizado porque el substrato comprende un primer resto escindible (CM1) que es escindible por una primera proteasa, y un segundo resto escindible (CM2) que es escindible por una segunda proteasa, y en donde el substrato comprende una secuencia de aminoácidos con una o más mutaciones de un aminoácido o dos aminoácidos de una cualquiera de las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 695, opcionalmente en donde el substrato comprende una secuencia de aminoácidos con una o más mutaciones de uno o dos aminoácidos de cualquiera de las SEQ ID Nº 9 - 24, 37 - 73, 83 - 353, 383 - 385, y 560 - 683. Reivindicación 91: Un polipéptido aislado que comprende un resto escindible (CM) caracterizado porque comprende una secuencia de aminoácidos con una o más mutaciones de uno o dos aminoácidos de cualquiera de las SEQ ID Nº 382, en donde el CM es un substrato para una proteasa. Reivindicación 115: El método de la reivindicación 114, caracterizado porque la enfermedad es cáncer, una infección, un trastorno inflamatorio, un trastorno cardiovascular, un trastorno neurodegenerativo o un trastorno autoinmunitario.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263370026P | 2022-08-01 | 2022-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR130077A1 true AR130077A1 (es) | 2024-10-30 |
Family
ID=87801206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230102011A AR130077A1 (es) | 2022-08-01 | 2023-07-31 | Substratos escindibles por proteasas, y métodos de uso de los mismos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250215095A1 (es) |
| EP (1) | EP4565250A1 (es) |
| JP (1) | JP2025525754A (es) |
| AR (1) | AR130077A1 (es) |
| TW (1) | TW202424183A (es) |
| WO (1) | WO2024030850A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| CN119241656B (zh) * | 2024-12-09 | 2025-04-18 | 青岛农业大学 | 小分子活性肽、组合物及其在制备具有抗氧化降血糖功效的产品中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| EP2398494A4 (en) | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and their methods of use |
| US9309325B2 (en) | 2009-05-07 | 2016-04-12 | The Regents Of The University Of California | Antibodies and methods of use thereof |
| RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
| US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| JP6826055B2 (ja) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄｌ１抗体、活性化可能抗ｐｄｌ１抗体、およびその使用方法 |
| MY194184A (en) | 2015-05-04 | 2022-11-17 | Cytomx Therapeutics Inc | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
| JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｃｄ１６６抗体、活性化可能抗ｃｄ１６６抗体、およびその使用方法 |
| HK1250037A1 (zh) | 2015-05-04 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-itga3抗体、可活化的抗-itga3抗体、及其使用方法 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| JP2020511130A (ja) | 2017-03-09 | 2020-04-16 | サイトメックス セラピューティクス インコーポレイテッド | Ｃｄ１４７抗体、活性化可能ｃｄ１４７抗体、ならびにその作製および使用の方法 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| EP3652210A1 (en) | 2017-07-14 | 2020-05-20 | CytomX Therapeutics, Inc. | Anti-cd166 antibodies and uses thereof |
| JP2020530554A (ja) | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| MX2020002198A (es) | 2017-08-30 | 2020-07-20 | Cytomx Therapeutics Inc | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| WO2019165143A1 (en) | 2018-02-21 | 2019-08-29 | Cytomx Therapeutics, Inc. | Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof |
| EP3762420A1 (en) | 2018-03-09 | 2021-01-13 | CytomX Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
| EP3769309A1 (en) | 2018-03-20 | 2021-01-27 | Cytomx Therapeutics Inc. | Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects |
| US20210324088A1 (en) | 2018-05-02 | 2021-10-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN113260383A (zh) | 2018-11-02 | 2021-08-13 | 西托姆克斯治疗公司 | 可活化的抗cd166抗体及其使用方法 |
| US12049505B2 (en) | 2018-12-06 | 2024-07-30 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| JP2022523200A (ja) | 2019-02-26 | 2022-04-21 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能な免疫チェックポイント阻害剤とコンジュゲートされた活性化可能な抗体の組み合わせ療法 |
| US20220226514A1 (en) | 2019-05-17 | 2022-07-21 | Cytomx Therapeutics, Inc. | Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates |
| EP3983440A1 (en) | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a neoadjuvant combination therapy for the treatment of cancer |
| US20220306745A1 (en) | 2019-06-13 | 2022-09-29 | Cytomx Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| EP4034171A1 (en) | 2019-09-23 | 2022-08-03 | Cytomx Therapeutics Inc. | Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof |
| BR112022013223A2 (pt) | 2020-01-06 | 2022-09-06 | Cytomx Therapeutics Inc | Compostos relacionados à auristatina, compostos conjugados de auristatina e métodos de uso dos mesmos |
| AU2021254279A1 (en) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics, Inc. | Compositions containing activatable antibodies |
| JP2023520922A (ja) | 2020-04-10 | 2023-05-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能サイトカイン構築物および関連組成物ならびに方法 |
-
2023
- 2023-07-31 AR ARP230102011A patent/AR130077A1/es unknown
- 2023-07-31 TW TW112128640A patent/TW202424183A/zh unknown
- 2023-07-31 WO PCT/US2023/071310 patent/WO2024030850A1/en not_active Ceased
- 2023-07-31 JP JP2025503386A patent/JP2025525754A/ja active Pending
- 2023-07-31 EP EP23761347.6A patent/EP4565250A1/en active Pending
-
2025
- 2025-03-17 US US19/081,340 patent/US20250215095A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250215095A1 (en) | 2025-07-03 |
| JP2025525754A (ja) | 2025-08-07 |
| WO2024030850A1 (en) | 2024-02-08 |
| EP4565250A1 (en) | 2025-06-11 |
| TW202424183A (zh) | 2024-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130077A1 (es) | Substratos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130079A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| Longworth | Conformations and interactions of excited states. II. Polystyrene, polypeptides, and proteins | |
| CO2022008004A2 (es) | Polipéptidos xten con código de barras y composiciones de estos, y métodos para preparar y usar los mismos | |
| MX2021006429A (es) | Sustratos escindibles con matriz de metaloproteasa, serina o cisteína escindible con proteasa y métodos de uso de estos. | |
| PE20010694A1 (es) | Plasmido autonomamente reproducible en bacterias corineformes | |
| ATE542894T1 (de) | Ausweitung des eukaryotischen genetischen codes | |
| DE602004022823D1 (de) | Virale vektoren | |
| TW200732472A (en) | Method for the recombinant expression of a polypeptide | |
| ES2061929T5 (es) | Nuevas enzimas proteoliticas y su utilizacion en detergentes. | |
| AR062300A2 (es) | Polipeptido que comprende una porcion inmunogenica de una proteina de prostata o su variante, molecula de adn, vector de expresion, celula huesped composicion farmaceutica, vacuna uso de dichas composiciones y vacunas para preparar medicamentos y proteina de fusion | |
| AR034663A1 (es) | Proceso para la purificacion de proteinas farmacologicamente activas mediante cromatografia de intercambio cationico | |
| ES2174097T3 (es) | Secuencias novedosas del termino 3' del genoma del virus de la hepatitis c y usos terapeuticos y diagnosticos de la misma. | |
| CY1109779T1 (el) | Αναστολεις της hcv ns-3 πρωτεασης σερινης | |
| AR053063A2 (es) | Proteina sustancialmente purificada y composicion farmaceutica que la comprende | |
| CO6251278A2 (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol | |
| NO900531D0 (no) | Ekspresjonssystemer for amideringsenzymer. | |
| DK1422237T3 (da) | Fremgangsmåder til rekombinant frembringelse af antifusogene peptider | |
| CY1114526T1 (el) | Κατασταλτικες πρωτεϊνες μιας πρωτεασης (protease) και χρησεις αυτων | |
| ZA202501953B (en) | Masking polypeptide, activatable novel prodrugs and methods of use thereof | |
| AR130640A1 (es) | Polipéptidos activados con proteasa | |
| DK1639104T3 (da) | Forbedrede proteaser og fremgangsmåder til fremstilling af disse | |
| AR130076A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| AR130080A1 (es) | Restos escindibles por proteasas, y métodos de uso de los mismos | |
| Bai et al. | Photocatalytic C–X Bond Cleavage Facilitates Peptide Synthesis |